title: Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.
authors.affiliation: Infectious Diseases Section, Medicine Service, Veterans Affairs San Diego Healthcare System Division of Infectious Diseases, University of California San Diego School of Medicine.
authors.forename: Michael N
authors.initials: MN
authors.lastname: Oxman
authors.affiliation: Geriatric Research, Education and Clinical Center, Durham Veterans Affairs Medical Center Department of Medicine, Duke University, Durham, North Carolina.
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Schmader
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006562:Herpes Zoster / Q000453:epidemiology* / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications*
chemical_list: D000970:Antineoplastic Agents; D053061:Herpes Zoster Vaccine
keywords: cancer chemotherapy; herpes zoster; immunization; varicella-zoster virus; zoster vaccine